Director/PDMR Shareholding
24 1월 2011 - 7:30PM
UK Regulatory
TIDMBII
NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITY OR CONNECTED PERSONS
This form is intended for use by an issuer to make a RIS notification required
by DR 3.3
(1) An issuer making a notification in respect of a transaction
relating to the shares or debentures of the issuer should complete boxes 1 to
16, 23 and 24.
(2) An issuer making a notification in respect of a derivative
relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14,
16, 23 and 24.
(3) An issuer making a notification in respect of options granted to
a director/person discharging managerial responsibilities should complete boxes
1 to 3 and 17 to 24.
(4) An issuer making a notification in respect of a financial
instrument relating to the shares of the issuer (other than a debenture) should
complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.
Please complete all relevant boxes should in block capital letters.
1. Name of the issuer 2. State whether the notification
relates to (i) a transaction
notified in accordance with DTR
3.1.2 R;
(ii) a disclosure made in
accordance with LR 9.8.6 R(1), or;
(iii) a disclosure made in
accordance with section 793 of the
Companies act (2006)
Biocompatibles International plc (i)
3. Name of person discharging 4. State whether notification relates
managerial responsibilities/ to a person connected with a person
director discharging managerial
responsibilities/director named in
3 and identify the connected person
Peter Geigle Not applicable
5. Indicate whether the notification 6. Description of shares (including
is in respect of a holding of the class), debentures or derivatives
person referred to in 3 or 4 or financial instruments relating
above or in respect of a to shares
non-beneficial interest
person referred to in 3. above Ordinary shares 21 53/94 pence
each
7. Name of registered shareholders 8 State the nature of the transaction
(s) and, if more than one, the
number of shares held by each of
them
as 3. above Sale
9. Number of shares, debentures or 10. Percentage of issued class
financial instruments relating to acquired (treasury shares of
shares acquired that class should not be taken
into account when calculating
percentage)
11. Number of shares, debentures or 12. Percentage of issued class
financial instruments relating to disposed (treasury shares of
shares disposed that class should not be taken
into account when calculating
percentage)
50,000 shares Total of 0.12%
13. Price per share or value of 14. Date and place of transaction
transaction
395p 19 January 2011
15. Total holding following notification 16. Date issuer informed of
and total percentage holding transaction
following notification (any treasury
shares should not be taken into
account when calculating percentage)
730,929 21 January 2011
1.78%
If a person discharging managerial responsibilities has been granted options by
the issuer complete the following boxes
17 Date of grant 18. Period during which or date
on which it can be exercised
19. Total amount paid (if any) for grant 20. Description of shares or
of the option debentures involved (class
and number)
21. Exercise price (if fixed at time of 22. Total number of shares or
grant) or indication that price is debentures over which options
to be fixed at the time of exercise held following notification
23. Any additional information 24. Name of contact and telephone
number for queries
Ian Ardill
Finance Director & Company
Secretary, Biocompatibles
International plc.
01252 732732
Name and signature of duly authorised officer of issuer responsible for
making notification
IAN ARDILL
__________________________________________________________
Date of notification 24 January 2011
END
Biocompatibles (LSE:BII)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Biocompatibles (LSE:BII)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Biocompatibles (London Stock Exchange)의 실시간 뉴스: 최근 기사 0
More Biocompatibles News Articles